Mark O'Neil-Johnson
Corporate Officer/Principal chez Sequoia Sciences, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Gary R. Eldridge | M | - |
Sequoia Sciences, Inc.
 Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 ans |
| William C. Rusnack | M | 79 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Joseph P. Conran | M | 78 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Stephen M. Notestine | M | 74 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | 25 ans |
| Michael J. Mertz | M | 53 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| James P. Bick | M | 63 |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Joel Schilling | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
| Michael Caparon | M | - |
Sequoia Sciences, Inc.
Sequoia Sciences, Inc. Pharmaceuticals: OtherHealth Technology Sequoia Sciences, Inc. engages in the development of new medicines for the treatment of bacterial infections and cancers. The firm's development programs consist of small molecules targeting bacterial infections and cancers, and vaccines for the treatment and prevention of recurrent urinary tract infections. The company was founded by Gary R. Eldridge, Jr. in 1999 and is headquartered in St. Louis, MO. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Mark O'Neil-Johnson
- Réseau Personnel
